PDS Biotechnology Corp - 16 Nov 2026 Form 4 Insider Report for PDS Biotechnology Corp (PDSB)

SEC form
4
Accepted by SEC
17 Nov 2026, 16:37:00 UTC
Source filing
View source filing
Filing notes and source

Key filing fact

PDS Biotechnology Corp filed Form 4 for PDS Biotechnology Corp (PDSB) on 17 Nov 2026.

Key facts

  • This page summarizes PDS Biotechnology Corp's Form 4 filing for PDS Biotechnology Corp (PDSB).
  • 1 reported transaction and 1 derivative row are listed below.
  • Accepted by SEC: 17 Nov 2026, 16:37.

Change

  • No earlier filing in this sequence is available for direct comparison.
  • Current net transaction value: $0.

Research use

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001472091 Primary reporting owner

PDS Biotechnology Corp

Relationship
Chief Scientific Officer

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

PDSB transaction Derivative

Employee Stock Option (Right to Buy)

Award

Transaction value
Shares
+299,567
Change %
Price
$0.000000*
Shares after
299,567
Date
16 Nov 2026
Ownership
Direct
Underlying class
Common Stock
Underlying amount
299,567
Exercise price
$0.9241
Footnotes
F1
* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

The option was granted on November 16, 2026, subject to stockholder approval of the Issuer's 2026 Equity Incentive Plan under Nasdaq Marketplace Rule 5635(c). The option is not exercisable until stockholder approval has been obtained. Contingent upon stockholder approval, the shares subject to the option shall vest in equal monthly installments over four (4) years, beginning on December 16, 2026, subject to the Reporting Person's continued service to the Issuer through each vesting date. In the event stockholder approval is not obtained pursuant to the terms of grant, then the Reporting Person shall surrender the option to the Company for cancellation.

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .